

Simparica™ Chewable Tablets for Dogs



Drug Class: Isoxazoline

API (Active Pharmaceutical Ingredient) : sarolaner

Mode of Action: Blocks GABA-receptors and glutamate-receptors in central nervous system of insects and acarines leading to parasite death

- Higher functional potency to block insect/acarine receptors compared to mammalian receptors

Pharmacology: Active against adult fleas, multiple tick and mite species demonstrated in field and/or laboratory* studies

- Fleas - *Ctenocephalides felis* (cat flea), *Ctenocephalides canis* (dog flea)
- Ticks - *Dermacentor reticulatus*, *Dermacentor variabilis**, *Ixodes hexagonus*, *Ixodes ricinus*, *Ixodes scapularis**, *Rhipicephalus sanguineus*, *Amblyomma americanum**, *Amblyomma maculatum**
- Mites - *Sarcoptes scabiei*, *Demodex canis** and *Otodectes cynotis**

Dosing: Monthly intervals of 2-4 mg/kg *per os* in dogs 8 weeks of age and older

- Available in five tablet sizes allow dosing of dogs from 1.3 - 40 kg with a single, chewable tablet

Simparica™ Chewable Tablets for Dogs



Indications:

- For the treatment of tick infestations with *Dermacentor reticulatus* (Ornate tick) *Ixodes hexagonus*, (Hedgehog tick), *Ixodes ricinus* (Castor Bean tick) and *Rhipicephalus sanguineus* (Brown Dog tick)
- For the treatment of flea infestations with *Ctenocephalides felis* and *Ctenocephalides canis*)
- For the treatment of sarcoptic mange (*Sarcoptes scabiei*) - 2 consecutive monthly doses
- Can be used as part of a treatment strategy for the control of flea allergy dermatitis

Product benefits - Efficacy

- Immediate and persistent tick killing activity for at least 5 weeks
 - Ticks on the dog prior to treatment are killed within 24 hours
 - Onset of efficacy is within 12 hours of tick (*I. ricinus*) attachments during the 28 days after administration (monthly dosing interval)
- Immediate and persistent flea killing activity against new infestation for at least 5 weeks
 - Onset of efficacy is within 8 hours of flea attachment during the 28 days after administration (monthly dosing interval)
- Kills newly emerged fleas on the dog before they can lay eggs, therefore preventing flea contamination in areas to which the dog has access
- Palatable tablets readily consumed by dogs when offered free choice; can be administered with or without food
 - 94% of dogs treated with Simparica™ voluntarily consumed the full tablet within 1 minute in a European field trial with over 800 client-owned dogs¹

Product benefits - Safety

- No adverse effects observed in laboratory margin of safety studies in dogs dosed at maximum label dose (4 mg/kg)
- No observed interactions with a variety of commonly prescribed veterinary medical products in clinical field trials
- In laboratory safety studies, no interactions observed when Simparica™ was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate.
- Well-tolerated in Collies with MDR1 -/- gene at 5 times label dose

¹ Study A161C-XC-12-083

Becskei C, Six R, Mahabir S, Bruno R, Stegemann M. Efficacy and Safety of PF-06450567

Administered Orally in the Treatment and Control of Natural Infestations of Fleas on Dogs Presented as Veterinary Patients in Europe. Study Number A161C-XC-12-083. 27 Aug 2014.